Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PIRS | US
-0.01
-0.06%
Healthcare
Biotechnology
30/06/2024
18/10/2024
16.92
16.85
16.92
16.85
Pieris Pharmaceuticals Inc. a clinical-stage biopharmaceutical company discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate elarekibep used for the treatment of asthma; and PRS-220 an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier AstraZeneca AB and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals Inc. was incorporated in 2000 and is headquartered in Boston Massachusetts.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
21.9%1 month
30.4%3 months
183.9%6 months
138.1%-
-
1.17
-
-
-1.47
1.76
-
-11.34M
22.07M
22.07M
-
-56.90
-
-97.30
-80.46
2.59
2.58
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.93
Range1M
1.47
Range3M
11.43
Rel. volume
0.45
Price X volume
48.08K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
RenovoRx Inc. Common Stock | RNXT | Biotechnology | 1 | 23.99M | 0.00% | n/a | 0.00% |
Bolt Technology Corp | BOLT | Biotechnology | 0.6264 | 23.97M | -1.82% | n/a | 22.00% |
ImmunoCellular Therapeutics Ltd | IMUC | Biotechnology | 0.14 | 23.43M | 1.45% | 0.02 | -82.78% |
Aligos Therapeutics Inc | ALGS | Biotechnology | 7.25 | 23.17M | 0.55% | n/a | 14.63% |
BioXcel Therapeutics Inc | BTAI | Biotechnology | 0.5658 | 23.05M | -0.74% | n/a | -139.46% |
Cyclo Therapeutics Inc | CYTH | Biotechnology | 0.774 | 22.21M | -1.39% | n/a | -58.50% |
Spruce Biosciences Inc | SPRB | Biotechnology | 0.519 | 21.44M | 1.76% | n/a | 6.24% |
NeuroSense Therapeutics Ltd. Ordinary Shares | NRSN | Biotechnology | 1.07 | 21.20M | -2.73% | n/a | -2.11% |
Cocrystal Pharma Inc | COCP | Biotechnology | 2.0718 | 21.08M | 1.56% | n/a | 10.24% |
Matinas BioPharma Holdings Inc | MTNB | Biotechnology | 4.12 | 20.86M | 0.98% | n/a | 16.97% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.9 | 19.65M | 2.38% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.03 | 18.60M | 5.10% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.538 | 7.80M | -6.65% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2201 | 3.95M | 4.26% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.76M | 1.92% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -12.28% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4801 | 0 | -10.26% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.045 | 0 | -2.34% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.47 | 0.53 | Cheaper |
Ent. to Revenue | 1.76 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 1.17 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 183.86 | 72.92 | Riskier |
Debt to Equity | - | -1.24 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 22.07M | 3.78B | Emerging |